What's Happening?
Howard R. Soule, Ph.D., will retire as the Chief Science Officer of the Prostate Cancer Foundation (PCF) at the end of March 2026, after nearly three decades of leadership. Dr. Soule has been instrumental in advancing prostate cancer research, contributing
to the development of 14 new life-extending therapies. Under his guidance, PCF has invested over $690 million in scientific investigations globally, pioneering research and collaborative models. Dr. Andrea Miyahira will succeed him, bringing her experience in overseeing PCF's research awards and mentoring early-career investigators.
Why It's Important?
Dr. Soule's retirement marks the end of an era for the PCF, which has been at the forefront of prostate cancer research and treatment innovations. His leadership has significantly impacted the field, improving patient outcomes and extending lives. The transition to Dr. Miyahira ensures continuity in PCF's mission to fund cutting-edge research and foster global collaborations. This leadership change is crucial for maintaining momentum in prostate cancer research, which remains a significant health challenge. The PCF's work continues to be vital in developing new therapies and improving the quality of life for patients worldwide.
What's Next?
Dr. Andrea Miyahira will lead PCF's scientific programs, focusing on accelerating research directions and fostering collaborations. Her leadership will be pivotal in continuing PCF's legacy of innovation and impact in prostate cancer research. The foundation will likely continue to expand its global footprint, funding research projects and supporting early-career scientists. This transition may also bring new strategic initiatives and partnerships, further advancing the fight against prostate cancer.
